Wells Fargo & Company Alkermes Plc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Alkermes Plc. stock. As of the latest transaction made, Wells Fargo & Company holds 69,041 shares of ALKS stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,041
Previous 72,653
4.97%
Holding current value
$2.05 Million
Previous $1.75 Million
10.4%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ALKS
# of Institutions
362Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$865 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$564 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$386 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$376 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$273 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.88B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...